查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1193311

全球儿科疫苗市场：按类型、技术、适应症分类：2021-2031 年全球机会分析和行业预测

Global Pediatric Vaccines Market By Type, By Technology, By Indication : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 310 Pages | 商品交期: 2-3个工作天内

价格

预计2021年全球儿科疫苗市场规模为213.7173亿美元，2022-2031年復合年增长率为5.4%，2031年达到363.9099亿美元。

儿科疫苗是给予儿童以获得获得性免疫力的生物製品。 接种疫苗有助于增强对特定病原体的免疫反应。 在许多国家，儿科疫苗在保持儿童健康方面发挥着重要作用，并在许多国家用于疾病预防战略。 由于病毒和细菌感染的数量不断增加，过去几年对疫苗的需求有所增加。 儿科疫苗主要用于不同年龄段的儿童，以改善免疫系统并确保在一生中免受各种形式的感染。

由于世界各地的国家免疫计划迅速采用儿科疫苗，预计儿科疫苗市场在预测期内将出现显着增长。 此外，肺炎球菌、流感和脑膜炎球菌在几个国家的流行率上升导致疫苗需求激增，进一步推动了市场增长。 然而，政府对批准新疫苗和召回某些产品的严格规定预计会阻碍市场增长。 另一方面，新兴市场需求的增加、新型疫苗研发活动的增加以及医疗费用的激增预计将为儿科疫苗市场提供重要的增长机会。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章全球儿科疫苗市场：按类型

  • 概览
    • 市场规模和预测
  • 单价疫苗
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 多价
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 5 章全球儿科疫苗市场：按技术分类

  • 概览
    • 市场规模和预测
  • 减毒活疫苗
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 灭活□□疫苗
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 类毒素疫苗
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 亚基、重组、多醣和结合疫苗
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 6 章全球儿科疫苗市场：按适应症分类

  • 概览
    • 市场规模和预测
  • 水痘
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 白喉、百日咳、破伤风
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 流感
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 人乳头瘤病毒
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 麻疹、腮腺炎、风疹
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 脑膜炎球菌感染
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 肺炎球菌感染
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 小儿麻痹症
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 轮状病毒
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他适应症
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 7 章全球儿科疫苗市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按类型
    • 北美市场规模和预测：按技术分类
    • 北美市场规模和预测：按适应症分类
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按类型
    • 欧洲市场规模和预测：按技术分类
    • 欧洲市场规模和预测：按适应症分类
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲地区
  • 亚太地区
    • 主要趋势和机会
    • 亚太市场规模和预测：按类型
    • 亚太市场规模和预测：按技术分类
    • 亚太地区的市场规模和预测：按适应症分类
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按类型
    • LAMEA 市场规模和预测：按技术分类
    • LAMEA 市场规模和预测：按适应症分类
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第八章公司情况

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第九章公司简介

  • AstraZeneca Plc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi Aventis
  • Serum Institute of India Pvt. Ltd.
Product Code: A00339

The global pediatric vaccine market accounted for $2,1371.73 million in 2021, and is expected to reach $ 3,6390.99 million by 2031, registering a CAGR of 5.4% from 2022 to 2031.

Pediatric vaccine is a biological preparation that is administered to produce acquired immunity in children. Administration of vaccines aids to enhance immune response against a specific pathogen. Pediatric vaccinations play a key role in sustaining children health across different countries; hence, they are used in various national disease-prevention strategies. Owing to the increased occurrence of both viral and bacterial infectious diseases, the demand for vaccines has grown over the past few years. Pediatric vaccinations are primarily provided to children of different ages, improving their immune system during their lives and ensuring defense against various forms of infectious diseases.

It is estimated that pediatric vaccine market is expected to experience significant market growth during the forecast period as there has been surge in adoption in several countries across the globe in the national immunization programs. In addition, rise in prevalence of pneumococcal, influenza, and meningococcal disease in several countries has led to upsurge in demand for vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products are expected to impede the market growth. In contrast, rise in demand in emerging markets, increase in R&D activities to develop new vaccines, and surge in healthcare spending are anticipated to provide significant growth opportunities for the pediatric vaccine market.

The pediatric vaccine market is segmented on the basis of type, technology, indication, and region. On the basis of type, the market is bifurcated into monovalent and multivalent. Depending on technology, it is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines. By indication, it is classified into varicella, diphtheria, pertussis & tetanus, influenza, human papilloma virus, measles, mumps & rubella, meningococcal disease, pneumococcal disease, polio, rotavirus, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global pediatric vaccine market. Key companies profiled in the report include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZeneca plc. GlaxoSmithKline plc., Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, and Novavax, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global paediatric vaccine market analysis from 2021 to 2031 to identify the prevailing global paediatric vaccine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global paediatric vaccine market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global global paediatric vaccine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technology

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines

By Type

  • Monovalent
  • Multivalent

By Indication

  • Varicella
  • Measles, Mumps and Rubella
  • Meningococcal Disease
  • Pneumococcal Disease
  • Polio
  • Rotavirus
  • Diphtheria, Pertussis and Tetanus
  • Influenza
  • Human Papilloma Virus
  • Other Indications

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • AstraZeneca Plc.
    • CSL Limited
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline plc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novavax, Inc.
    • Pfizer Inc.
    • Sanofi Aventis
    • Serum Institute of India Pvt. Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Monovalent
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Multivalent
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Live Attenuated Vaccines
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Inactivated Vaccines
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Toxoid Vaccines
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country
  • 5.5 Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market share analysis by country

CHAPTER 6: GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Varicella
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Diphtheria, Pertussis and Tetanus
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Influenza
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country
  • 6.5 Human Papilloma Virus
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market share analysis by country
  • 6.6 Measles, Mumps and Rubella
    • 6.6.1 Key market trends, growth factors and opportunities
    • 6.6.2 Market size and forecast, by region
    • 6.6.3 Market share analysis by country
  • 6.7 Meningococcal Disease
    • 6.7.1 Key market trends, growth factors and opportunities
    • 6.7.2 Market size and forecast, by region
    • 6.7.3 Market share analysis by country
  • 6.8 Pneumococcal Disease
    • 6.8.1 Key market trends, growth factors and opportunities
    • 6.8.2 Market size and forecast, by region
    • 6.8.3 Market share analysis by country
  • 6.9 Polio
    • 6.9.1 Key market trends, growth factors and opportunities
    • 6.9.2 Market size and forecast, by region
    • 6.9.3 Market share analysis by country
  • 7.0 Rotavirus
    • 7.0.1 Key market trends, growth factors and opportunities
    • 7.0.2 Market size and forecast, by region
    • 7.0.3 Market share analysis by country
  • 7.1 Other Indications
    • 7.1.1 Key market trends, growth factors and opportunities
    • 7.1.2 Market size and forecast, by region
    • 7.1.3 Market share analysis by country

CHAPTER 7: GLOBAL PEDIATRIC VACCINES MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
    • 7.2.3 North America Market size and forecast, by Technology
    • 7.2.4 North America Market size and forecast, by Indication
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Type
      • 7.2.5.1.3 Market size and forecast, by Technology
      • 7.2.5.1.4 Market size and forecast, by Indication
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Type
      • 7.2.5.2.3 Market size and forecast, by Technology
      • 7.2.5.2.4 Market size and forecast, by Indication
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Type
      • 7.2.5.3.3 Market size and forecast, by Technology
      • 7.2.5.3.4 Market size and forecast, by Indication
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
    • 7.3.3 Europe Market size and forecast, by Technology
    • 7.3.4 Europe Market size and forecast, by Indication
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Type
      • 7.3.5.1.3 Market size and forecast, by Technology
      • 7.3.5.1.4 Market size and forecast, by Indication
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Type
      • 7.3.5.2.3 Market size and forecast, by Technology
      • 7.3.5.2.4 Market size and forecast, by Indication
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Type
      • 7.3.5.3.3 Market size and forecast, by Technology
      • 7.3.5.3.4 Market size and forecast, by Indication
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Type
      • 7.3.5.4.3 Market size and forecast, by Technology
      • 7.3.5.4.4 Market size and forecast, by Indication
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Type
      • 7.3.5.5.3 Market size and forecast, by Technology
      • 7.3.5.5.4 Market size and forecast, by Indication
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Type
      • 7.3.5.6.3 Market size and forecast, by Technology
      • 7.3.5.6.4 Market size and forecast, by Indication
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Technology
    • 7.4.4 Asia-Pacific Market size and forecast, by Indication
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Type
      • 7.4.5.1.3 Market size and forecast, by Technology
      • 7.4.5.1.4 Market size and forecast, by Indication
      • 7.4.5.2 Japan
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Type
      • 7.4.5.2.3 Market size and forecast, by Technology
      • 7.4.5.2.4 Market size and forecast, by Indication
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Type
      • 7.4.5.3.3 Market size and forecast, by Technology
      • 7.4.5.3.4 Market size and forecast, by Indication
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Type
      • 7.4.5.4.3 Market size and forecast, by Technology
      • 7.4.5.4.4 Market size and forecast, by Indication
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Type
      • 7.4.5.5.3 Market size and forecast, by Technology
      • 7.4.5.5.4 Market size and forecast, by Indication
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Type
      • 7.4.5.6.3 Market size and forecast, by Technology
      • 7.4.5.6.4 Market size and forecast, by Indication
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
    • 7.5.3 LAMEA Market size and forecast, by Technology
    • 7.5.4 LAMEA Market size and forecast, by Indication
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Type
      • 7.5.5.1.3 Market size and forecast, by Technology
      • 7.5.5.1.4 Market size and forecast, by Indication
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Type
      • 7.5.5.2.3 Market size and forecast, by Technology
      • 7.5.5.2.4 Market size and forecast, by Indication
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Type
      • 7.5.5.3.3 Market size and forecast, by Technology
      • 7.5.5.3.4 Market size and forecast, by Indication
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Type
      • 7.5.5.4.3 Market size and forecast, by Technology
      • 7.5.5.4.4 Market size and forecast, by Indication

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 AstraZeneca Plc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 CSL Limited
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Emergent BioSolutions Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 GlaxoSmithKline plc.
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Johnson & Johnson
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Merck & Co., Inc.
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Novavax, Inc.
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Pfizer Inc.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Sanofi Aventis
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Serum Institute of India Pvt. Ltd.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. GLOBAL PEDIATRIC VACCINES MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. UK GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 96. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 97. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 98. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 99. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 100. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 101. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 102. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 103. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 104. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 105. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 106. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 107. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 108. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 109. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 110.ASTRAZENECA PLC.: COMPANY SNAPSHOT
  • TABLE 111.ASTRAZENECA PLC.: OPERATING SEGMENTS
  • TABLE 112.ASTRAZENECA PLC.: PRODUCT PORTFOLIO
  • TABLE 113.ASTRAZENECA PLC.: NET SALES
  • TABLE 114.ASTRAZENECA PLC.: KEY STRATERGIES
  • TABLE 115.CSL LIMITED: COMPANY SNAPSHOT
  • TABLE 116.CSL LIMITED: OPERATING SEGMENTS
  • TABLE 117.CSL LIMITED: PRODUCT PORTFOLIO
  • TABLE 118.CSL LIMITED: NET SALES
  • TABLE 119.CSL LIMITED: KEY STRATERGIES
  • TABLE 120.EMERGENT BIOSOLUTIONS INC.: COMPANY SNAPSHOT
  • TABLE 121.EMERGENT BIOSOLUTIONS INC.: OPERATING SEGMENTS
  • TABLE 122.EMERGENT BIOSOLUTIONS INC.: PRODUCT PORTFOLIO
  • TABLE 123.EMERGENT BIOSOLUTIONS INC.: NET SALES
  • TABLE 124.EMERGENT BIOSOLUTIONS INC.: KEY STRATERGIES
  • TABLE 125.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 126.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 127.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 128.GLAXOSMITHKLINE PLC.: NET SALES
  • TABLE 129.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
  • TABLE 130.JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 131.JOHNSON & JOHNSON: OPERATING SEGMENTS
  • TABLE 132.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 133.JOHNSON & JOHNSON: NET SALES
  • TABLE 134.JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 135.MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 136.MERCK & CO., INC.: OPERATING SEGMENTS
  • TABLE 137.MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 138.MERCK & CO., INC.: NET SALES
  • TABLE 139.MERCK & CO., INC.: KEY STRATERGIES
  • TABLE 140.NOVAVAX, INC.: COMPANY SNAPSHOT
  • TABLE 141.NOVAVAX, INC.: OPERATING SEGMENTS
  • TABLE 142.NOVAVAX, INC.: PRODUCT PORTFOLIO
  • TABLE 143.NOVAVAX, INC.: NET SALES
  • TABLE 144.NOVAVAX, INC.: KEY STRATERGIES
  • TABLE 145.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 146.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 147.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 148.PFIZER INC.: NET SALES
  • TABLE 149.PFIZER INC.: KEY STRATERGIES
  • TABLE 150.SANOFI AVENTIS: COMPANY SNAPSHOT
  • TABLE 151.SANOFI AVENTIS: OPERATING SEGMENTS
  • TABLE 152.SANOFI AVENTIS: PRODUCT PORTFOLIO
  • TABLE 153.SANOFI AVENTIS: NET SALES
  • TABLE 154.SANOFI AVENTIS: KEY STRATERGIES
  • TABLE 155.SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 156.SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS
  • TABLE 157.SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 158.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES
  • TABLE 159.SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.GLOBAL PEDIATRIC VACCINES MARKET SEGMENTATION
  • FIGURE 2.GLOBAL PEDIATRIC VACCINES MARKET,2021-2031
  • FIGURE 3.GLOBAL PEDIATRIC VACCINES MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.GLOBAL PEDIATRIC VACCINES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.GLOBAL PEDIATRIC VACCINES MARKET,BY TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF MONOVALENT GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MULTIVALENT GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 15.GLOBAL PEDIATRIC VACCINES MARKET,BY TECHNOLOGY,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF LIVE ATTENUATED VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF INACTIVATED VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TOXOID VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 20.GLOBAL PEDIATRIC VACCINES MARKET,BY INDICATION,2021(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF VARICELLA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DIPHTHERIA, PERTUSSIS AND TETANUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF INFLUENZA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HUMAN PAPILLOMA VIRUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF MEASLES, MUMPS AND RUBELLA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF MENINGOCOCCAL DISEASE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF PNEUMOCOCCAL DISEASE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 28.COMPARATIVE SHARE ANALYSIS OF POLIO GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF ROTAVIRUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
  • FIGURE 31.GLOBAL PEDIATRIC VACCINES MARKET BY REGION,2021
  • FIGURE 32.U.S. GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 33.CANADA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 34.MEXICO GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 35.GERMANY GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 36.FRANCE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 37.UK GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 38.ITALY GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 39.SPAIN GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 41.CHINA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 42.JAPAN GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 43.INDIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 44.AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 45.SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 46.REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 47.BRAZIL GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 48.SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 49.SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 50.REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
  • FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 55.COMPETITIVE DASHBOARD
  • FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 57.ASTRAZENECA PLC..: NET SALES ($MILLION)
  • FIGURE 58.CSL LIMITED.: NET SALES ($MILLION)
  • FIGURE 59.EMERGENT BIOSOLUTIONS INC..: NET SALES ($MILLION)
  • FIGURE 60.GLAXOSMITHKLINE PLC..: NET SALES ($MILLION)
  • FIGURE 61.JOHNSON & JOHNSON.: NET SALES ($MILLION)
  • FIGURE 62.MERCK & CO., INC..: NET SALES ($MILLION)
  • FIGURE 63.NOVAVAX, INC..: NET SALES ($MILLION)
  • FIGURE 64.PFIZER INC..: NET SALES ($MILLION)
  • FIGURE 65.SANOFI AVENTIS.: NET SALES ($MILLION)
  • FIGURE 66.SERUM INSTITUTE OF INDIA PVT. LTD..: NET SALES ($MILLION)